All Outputs (2)

Anwendungsbeobachtungs-Studie zur praktischen Anwendung von Klinischer Pharmazie bei COVID-19 Therapie. (2024)
Presentation / Conference Contribution
STOIBER, A., GRAY, G., SAILER, G., HUF, W. and TONNA, A. 2024. Anwendungsbeobachtungs-Studie zur praktischen Anwendung von Klinischer Pharmazie bei COVID-19 Therapie = Observational study on the practical application of clinical pharmacy in COVID-19 treatment. Presented at the 2024 Austrian Society for Hospital Pharmacy spring meeting, 24-25 May 2024, Vienna, Austria.

This presentation covers an observational study looking at Paxlovid as a treatment for COVID-19, undertaken at the Klinik Hietzing in Austria.

A description of pharmacists' interventions to optimise the treatment of adults with orally available Covid-drug, Paxlovid. (2024)
Presentation / Conference Contribution
STOIBER, A., GRAY, G., SAILER, G., HUF, W. and TONNA, A. 2024. A description of pharmacists' interventions to optimise the treatment of adults with orally available Covid-drug, Paxlovid. Poster presented at the 28th European Association of Hospital Pharmacists (EAHP) annual congress 2024 (EAHP 2024): sustainable healthcare; opportunities and strategies, 20-22 March 2024, Bordeaux, France.

Paxlovid ®, the only orally available COVID drug, consists of two main components: Nirmatrelvir and Ritonavir. Ritonavir is known for the potent inhibition of CYP (cytochrome P450) enzymes in the liver mainly of CYP3A4, resulting in a large number of... Read More about A description of pharmacists' interventions to optimise the treatment of adults with orally available Covid-drug, Paxlovid..